Syndax Pharmaceuticals Inc (SNDX)

18.80
+0.14(+0.75%)
Pre Market
20.34
+1.54(+8.19%)
- Real-time Data
  • Volume:
    450,083
  • Bid/Ask:
    19.30/22.55
  • Day's Range:
    18.49 - 18.87

SNDX Overview

Prev. Close
18.66
Day's Range
18.49-18.87
Revenue
1.52M
Open
18.7
52 wk Range
13.04-27.79
EPS
-1.89
Volume
450,083
Market Cap
914.2M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
458,737
P/E Ratio
-
Beta
1.56
1-Year Change
35.25%
Shares Outstanding
48,627,611
Next Earnings Date
Nov 11, 2021
What is your sentiment on Syndax Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Syndax Pharmaceuticals Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong SellStrong BuySellBuyBuy
SummaryNeutralStrong BuyNeutralStrong BuyStrong Buy

Syndax Pharmaceuticals Inc Company Profile

Syndax Pharmaceuticals Inc Company Profile

Employees
43

Syndax Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing a pipeline of cancer therapies. The Company’s lead product candidates include SNDX-5613 and SNDX-6352 (axatilimab). The Company’s clinical-stage product candidate, SNDX-5613, is the orally available, small molecule inhibitor of the interaction of menin with the mixed lineage leukemia protein (MLL). It is developing SNDX-5613 as a targeted therapy to treat two genetically defined acute leukemias: mixed lineage leukemia-rearranged (MLLr), and acute myeloid leukemia (AML), with a mutated nucleophosmin 1. The Company’s products candidate also includes entinostat, once-weekly, oral, small molecule, and Class I histone deacetylases (HDAC) inhibitor that being evaluated in the Phase III E2112 registrational clinical trial in combination with exemestane for hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer.

Read More
  • Buy now👍
    0
    • Quick Buy call on ADVM. CMP 4.0 fell 60% today.. going to recover 40% in one hour. Hurry make your profit 40% today..
      1
      • Strong buy call with 30% upside today. Buy SNDX pharma CMP: 15.95 today target 21$
        0
        • Company chairman bought $197k worth shares very recently at 14.10..tjose who have webul account please check News info of this share... Very good positivr sign for share price to climb up drastically. Short term target before May expiry 42$ per share. Share may rise sharply tomorro..
          0
          • Mark my words the graph is very strong and any time may shootup strongly
            0
            • Strong upside seen in intraday chart.. any time will break today high..
              1
              • String upside seen in intraday chart.. any time will break today high
                1
                • Morning All, One more Quick Buy call on SNDX pharma. CMP 14.98 intraday target 17.40$.. hurry quick buy before surges.. next week 25$ target.. bet in options and make huge returns
                  1
                  • Form 4 for director buying over 13000 shares at $14.11 average
                    0
                    • sources?
                      0
                  • Buy now at 14.01..
                    0
                    • Quick buy call on SNDX pharma. Its almost 10% after i post my message... still expecting huge upside today of another 30%.. expecting 17.5 call to surge 400%.. quick buy and have a good day.
                      0
                      • you are right good for u
                        0
                        • Quick buy call on SNDX pharma with 20% upside cap today..
                          0
                          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.